EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Surgery, chemoradiotherapy, or chemoradiation plus immunotherapy: Treatment strategies for nonmetastatic anal squamous cell carcinoma

Fang He, Mo Chen, Qi-Jun Yao, Zhi-Min Liu, Yandong Zhao, Fengyun Pei, Jian Zheng, Yuan-Hong Gao, Jun Huang

Translational Oncology · 2024-12 · 50 · 102133

DOI: 10.1016/j.tranon.2024.102133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Translational Oncology, 2024-12. Verfasst von Fang He und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Cen…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current standard of care for anal squamous cell carcinoma (ASCC) is definitive concurrent chemoradiotherapy (CRT). However, about a third of patients may experience treatment failure. Recently, immunotherapy has emerged as a novel strategy for metastatic ASCC patients. We evaluated the efficacy and safety of surgery, CRT alone, and CRT with immunotherapy (CRT-I) in 100 nonmetastatic ASCC patients, treated from April 2012 through May 2023, by determining survival outcomes and acute adverse events. The median (range) follow-up was 30.7 (7.6 to 134.9) months. The study cohort 3-year overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional recurrence-free survival (LRFS) rates were 80.7 %, 62.2 %, 71.1 %, and 67.6 %, respectively. The Surgery group had significantly lower rates than the CRT and CRT-I groups for 3-year PFS (33.1% vs. 65.2% vs. 92.9 %, P < 0.001), DMFS (46.7% vs. 74.6% vs. 92.9 %, P = 0.002) and LRFS (37.0% vs. 73.3% vs. 92.9 %, P < 0.001), respectively. All patients receiving CRT-I were alive at last follow-up. Of 100 patients, 26 (26.0 %) experienced severe (≥ grade 3) acute toxicity. Of 24 patients receiving CRT-I, 8 (33.3 %) had severe acute toxicity. Using immunohistochemistry, peritumoural stromal infiltration by CD8+ T cells was significantly higher after CRT-I compared to before CRT-I and to after CRT alone. The addition of immunotherapy to CRT may be an effective first-line treatment option with favourable survival outcomes and acceptable toxicity for patients with ASCC. A prospective, randomized trial assessing the efficacy of CRT combined with a PD-1 inhibitor in patients with locally advanced ASCC is in progress.

Schlagwörter

Stichwörter der Autor:innen

Anal canalChemoradiotherapyImmunotherapySquamous cell carcinomaSurgery

Autor:innen und Institutionen

  • Department of Radiation Oncology, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong, China; Department of Ra…
  • Department of Genitourinary oncology, The First People's Hospital of Foshan, Foshan, Guangdong, China.
  • Biomedical Innovation Centre, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China; Department of Colorectal Surgery, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Dise…
  • Biomedical Innovation Centre, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China; Department of Pathology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The…
  • Department of Radiation Oncology, Guangdong Provincial Key Laboratory of Colorectal and Pelvic Floor Diseases, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China; Biomedical Innovation Ce…
  • Department of Radiation Oncology, Sun Yat-sen University Cancer Centre, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre for Cancer Medicine, Guangzhou, Guangdong, China. Electronic addre…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

He, F., Chen, M., Yao, Q. J., Liu, Z. M., Zhao, Y., Pei, F., Zheng, J., Gao, Y. H., & Huang, J. (2024). Surgery, chemoradiotherapy, or chemoradiation plus immunotherapy: Treatment strategies for nonmetastatic anal squamous cell carcinoma. Translational Oncology, 50, 102133. https://doi.org/10.1016/j.tranon.2024.102133

Vancouver

He F, Chen M, Yao QJ, Liu ZM, Zhao Y, Pei F, et al. Surgery, chemoradiotherapy, or chemoradiation plus immunotherapy: Treatment strategies for nonmetastatic anal squamous cell carcinoma. Translational Oncology. 2024;50:102133. doi:10.1016/j.tranon.2024.102133

BibTeX
@article{He2024,
  author = {He, Fang and Chen, Mo and Yao, Qi-Jun and Liu, Zhi-Min and Zhao, Yandong and Pei, Fengyun and Zheng, Jian and Gao, Yuan-Hong and Huang, Jun},
  title = {Surgery, chemoradiotherapy, or chemoradiation plus immunotherapy: Treatment strategies for nonmetastatic anal squamous cell carcinoma},
  journal = {Translational Oncology},
  year = {2024},
  volume = {50},
  pages = {102133},
  doi = {10.1016/j.tranon.2024.102133}
}
Kostenlos starten →